Adcytherix

Adcytherix develops novel antibody-drug conjugates (ADCs) for unmet needs, focusing on a lead asset targeting integrin proteins on tumor cells.
Domain
Healthcare
Status
Current Private Investment
Stage of Initial Investment
Seed
Initial Investment Year
2024